blue cross blue shield coverage for glp 1 of Michigan GLP-1 Changes Explained — Restorative Compounding Pharmacy + Wellness does blue cross blue shield

,

Sergey Terushkin, MD, FACS Key Takeaways: Mounjaro (tirzepatide) targets GIP + GLP-1 receptors , while Ozempic (semaglutide) targets GLP-1 only Clinical studies show greater average weight loss with tirzepatide in many patients Both medications require BMI 30 or 27 with weight-related conditions Common side effects include nausea, GI discomfort, and appetite changes , usually improving with dose adjustment Insurance coverage varies more common for diabetes than weight loss Prescription required treatment must be doctor-guided and medically supervised If you are deciding between Mounjaro and Ozempic for weight loss in 2026, the key difference is that tirzepatide (Mounjaro) activates two metabolic pathways (GIP + GLP-1), while semaglutide (Ozempic) activates one (GLP-1) which may impact weight loss outcomes and tolerability

Protein at every meal and two weekly strength sessions become the routine that protects your muscle from day one

Increased alpha 2-adrenergic binding sites and antilipolytic effect in adipocytes from genetically obese rats

See our broader approach to Obesity & Weight Loss

Its working